DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cabergoline Effect on Blood Sugar in Type 2 Diabetics

Information source: Mashhad University of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Type 2

Intervention: Cabergoline (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: Mashhad University of Medical Sciences


Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.

Clinical Details

Official title: Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: FBS (fasting blood sugar)

Secondary outcome: HbA1C


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Type 2 diabetes

- HbA1C>7

Exclusion Criteria:

- HbA1C>10

- Psychiatric disorders

Locations and Contacts

Additional Information

Starting date: January 2012
Last updated: October 24, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017